1 Statement of Intent. The general court recognizes its obligation to ensure the medical oversight board adheres to standard state conflict of interest provisions. Even the perception of conflict of interest could adversely impact the board's statutory role to monitor and contribute to the oversight of the clinical, quality, and public health related matters of the use of cannabis for therapeutic purposes. The general court also recognizes its obligation to protect the health and safety of the 8,302 qualified patients enrolled in the therapeutic cannabis program (TCP 2019 Annual Data Report). The United States Surgeon General and the Centers for Disease Control and Prevention have issued recent advisories on the health risks and side-effects of marijuana use.

2 Medical Director; Review Required. The medical director, department of health and human services, as chairperson of the therapeutic cannabis medical oversight board, is directed to conduct a review of the current medical and scientific evidence pertaining to approved qualifying medical conditions under RSA 126-X:1, IX and make recommendations to the commissioner to add or remove qualifying medical conditions pursuant to subparagraph RSA 126-X:12, IV(a). This review should include, but not be limited to, recent scientific advances in treatment for glaucoma, epilepsy, PTSD and autism spectrum disorder now in use since passage of the therapeutic cannabis law in 2013.

3 Report Required. The commissioner of the department of health and human services shall report on recommended legislation based on the medical director's findings no later than 90 days after the passage of this act to the joint legislative oversight committee on health and human services established pursuant to RSA 126-A:13.

4 Therapeutic Cannabis Medical Oversight Board; Membership. Amend the introductory paragraph of RSA 126-X:12, II to read as follows:

II. The board shall consist of the medical director, department of health and human services, or designee, a qualifying patient, appointed by the commissioner of the department, a clinical representative from an alternative treatment center, appointed by the commissioner, and 10 medical providers also appointed by the commissioner. The medical provider members shall represent the following fields:

5 Effective Date.

I. Sections 1 and 4 of this act shall take effect 60 days after its passage.

II. The remainder of this act shall take effect upon its passage.

1 Statement of Intent. The general court recognizes its obligation to ensure the medical oversight board adheres to standard state conflict of interest provisions. Even the perception of conflict of interest could adversely impact the board's statutory role to monitor and contribute to the oversight of the clinical, quality, and public health related matters of the use of cannabis for therapeutic purposes. The general court also recognizes its obligation to protect the health and safety of the 8,302 qualified patients enrolled in the therapeutic cannabis program (TCP 2019 Annual Data Report). The United States Surgeon General and the Centers for Disease Control and Prevention have issued recent advisories on the health risks and side-effects of marijuana use.

2 Medical Director; Review Required. The medical director, department of health and human services, as chairperson of the therapeutic cannabis medical oversight board, is directed to conduct a review of the current medical and scientific evidence pertaining to approved qualifying medical conditions under RSA 126-X:1, IX and make recommendations to the commissioner to add or remove qualifying medical conditions pursuant to subparagraph RSA 126-X:12, IV(a). This review should include, but not be limited to, recent scientific advances in treatment for glaucoma, epilepsy, PTSD and autism spectrum disorder now in use since passage of the therapeutic cannabis law in 2013.

3 Report Required. The commissioner of the department of health and human services shall report on recommended legislation based on the medical director's findings no later than 90 days after the passage of this act to the joint legislative oversight committee on health and human services established pursuant to RSA 126-A:13.

4 Therapeutic Cannabis Medical Oversight Board; Membership. Amend the introductory paragraph of RSA 126-X:12, II to read as follows:

II. The board shall consist of the medical director, department of health and human services, or designee, a qualifying patient, appointed by the commissioner of the department, a clinical representative from an alternative treatment center, appointed by the commissioner, and 10 medical providers also appointed by the commissioner. Board members shall, prior to participating in any matter, disclose whether they have a private, financial, or pecuniary interest which may directly or indirectly affect or influence the performance of their duties relative to that matter. The medical provider members shall represent the following fields:

5 Effective Date.

I. Sections 1 and 4 of this act shall take effect 60 days after its passage.

II. The remainder of this act shall take effect upon its passage.